Reuters: Regulatory News: FDA staff raise safety concerns over Sanofi MS drug Lemtrada

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA staff raise safety concerns over Sanofi MS drug Lemtrada Nov 8th 2013, 14:16 Fri Nov 8, 2013 9:16am EST Nov 8 (Reuters) - U.S. regulatory officials raised concerns about "multiple serious and potentially fatal safety issues" in patients given Sanofi's new multiple sclerosis drug Lemtrada, raising concerns over its approval. Shares in Sanofi fell 2 percent after the documents were posted on the FDA's website on Friday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions